{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:06:41Z","timestamp":1751519201009},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"The Promotional Project of Guangxi Medical and Health Appropriate Technology","award":["S201518"],"award-info":[{"award-number":["S201518"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0515-4","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T13:21:31Z","timestamp":1489670491000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1\u00a0year follow up: a systematic review and meta-analysis of 6 randomized controlled trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Pravesh Kumar","family":"Bundhun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra Mouli","family":"Yanamala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"4","key":"515_CR1","doi-asserted-by":"crossref","first-page":"e0154064","DOI":"10.1371\/journal.pone.0154064","volume":"11","author":"PK Bundhun","year":"2016","unstructured":"Bundhun PK, Bhurtu A, Soogund MZ, Long MY. Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 10 randomized controlled trials. PLoS ONE. 2016;11(4):e0154064.","journal-title":"PLoS ONE"},{"issue":"5","key":"515_CR2","doi-asserted-by":"crossref","first-page":"e2651","DOI":"10.1097\/MD.0000000000002651","volume":"95","author":"PK Bundhun","year":"2016","unstructured":"Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(5):e2651.","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"515_CR3","doi-asserted-by":"crossref","first-page":"e3276","DOI":"10.1097\/MD.0000000000003276","volume":"95","author":"PK Bundhun","year":"2016","unstructured":"Bundhun PK, Pursun M, Teeluck AR, Long MY. Are everolimus-eluting stents associated with better clinical outcomes compared to other drug-eluting stents in patients with type 2 diabetes mellitus?: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(14):e3276.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"515_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MCA.0000000000000222","volume":"26","author":"L Qi-Hua","year":"2015","unstructured":"Qi-Hua L, Qi Z, Yu Z, et al. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-elutingversus zotarolimus-eluting stents: a meta-analysis. Coron Artery Dis. 2015;26(3):259\u201365.","journal-title":"Coron Artery Dis"},{"key":"515_CR5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ijcard.2015.02.097","volume":"201","author":"H Gu","year":"2015","unstructured":"Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015;201:552\u201360.","journal-title":"Int J Cardiol"},{"issue":"17","key":"515_CR6","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"key":"515_CR7","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008:187-241.","DOI":"10.1002\/9780470712184.ch8"},{"key":"515_CR8","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"5","key":"515_CR9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2012.11.015","volume":"61","author":"KW Park","year":"2013","unstructured":"Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-elutingresolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013;61(5):536\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"515_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2261-13-65","volume":"13","author":"JM Lee","year":"2013","unstructured":"Lee JM, Youn TJ, Park JJ, et al. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stentsin a real world setting of coronary intervention in Korea. BMC Cardiovasc Disord. 2013;13:65.","journal-title":"BMC Cardiovasc Disord"},{"key":"515_CR11","doi-asserted-by":"crossref","unstructured":"Poorhoseini HR, Kassaian SE, Hoseini K, et al. Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patientswith coronary artery disease: data from the THCRIC registry. Ther Adv Cardiovasc Dis. 2016;10(4):206-13.","DOI":"10.1177\/1753944716629868"},{"issue":"7","key":"515_CR12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ccd.25469","volume":"84","author":"A Omar","year":"2014","unstructured":"Omar A, Torguson R, Kitabata H, et al. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-elutingstents and bare metal stents in patients with acute coronary syndrome. Catheter Cardiovasc Interv. 2014;84(7):1053\u201360.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"515_CR13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00392-013-0546-5","volume":"102","author":"I Akin","year":"2013","unstructured":"Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA. Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol. 2013;102(5):371\u201381.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"515_CR14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.amjcard.2016.03.005","volume":"117","author":"F D'Ascenzo","year":"2016","unstructured":"D'Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714\u201323.","journal-title":"Am J Cardiol"},{"issue":"11","key":"515_CR15","first-page":"20813","volume":"8","author":"L Lin","year":"2015","unstructured":"Lin L, Jin C, Wei X, et al. Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heartdisease between diabetic and non-diabetic patients. Int J Clin Exp Med. 2015;8(11):20813\u201320.","journal-title":"Int J Clin Exp Med"},{"issue":"22","key":"515_CR16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jacc.2013.07.044","volume":"62","author":"J Mehilli","year":"2013","unstructured":"Mehilli J, Richardt G, Valgimigli M, et al. ISAR-LEFT-MAIN 2 Study Investigators. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2013;62(22):2075\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"9915","key":"515_CR17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","volume":"383","author":"C Birgelen von","year":"2014","unstructured":"von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring apercutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413\u201323.","journal-title":"Lancet"},{"issue":"25 Pt A","key":"515_CR18","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.04.013","volume":"63","author":"KW Park","year":"2014","unstructured":"Park KW, Kang SH, Kang HJ, et al. HOST\u2013ASSURE Investigators. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-elutingstents & anti-platelet regimen), a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2014;63(25 Pt A):2805\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"515_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1004130","volume":"363","author":"PW Serruys","year":"2010","unstructured":"Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136\u201346.","journal-title":"N Engl J Med"},{"issue":"15","key":"515_CR20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jacc.2012.01.008","volume":"59","author":"C Birgelen von","year":"2012","unstructured":"von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350\u201361.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0515-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T12:45:14Z","timestamp":1498394714000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0515-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0515-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"article-number":"84"}}